3 new three-plate pharmaceutical companies turn to the branch of the board! Cofeiping, Jiang bio, Jinbo bio IPO accepted

Recently, Applications from Jiangsu Kofipin Pharmaceutical Co., Ltd(hereinafter referred to as Kofiping), Shanghai Jiang Biotech Co., Ltd(hereinafter referred to as Jiangbio) and Shanxi Jinbo Biopharmaceutical Co., Ltd(hereinafter referred to as Jinbo Bio) were accepted. According to the prospectus disclosure, all three enterprises have chosen the first set of standard listing, that is, "the expected market value is not less than RMB 1 billion, the last two years of net profit is positive and cumulative net profit is not less than RMB50 million, or the expected market value is not less than RMB1 billion, the most recent year net profit is positive and operating income is not less than RMB 100 million." It is worth noting that Kofipin, Jiangjiang Bio and Jinbo Bio were listed on the new three boards in February 2017, December 2015 and July 2015, respectively. KofiPing: 3 years of cumulative research and development investment of 159 million yuan, raised 1.596 billion yuan Kofiping was established in 2000, focusing on cardiovascular and cerebrovascular, digestive system and other major diseases and chronic diseases in the field, committed to high clinical value of innovative drugs research and development and commercializationSince its inception, Cophypin has been in the market for 2 drugs of dansanketa sulfonate, 2 drugs for cerebral pulising particles, and 10 drugs in the research, including four innovative drugs in clinical research - konolazan at conesic acid, vonorozan injection of acetate, injection of methicillin silver ninceyl B and methicillamine silver b tablets, and 6 clinically pre-research phase of the high-selective small-molecule target inge. From 2017 to 2019, Kofiping's operating income was RMB1,104 million, RMB748 million and RMB774 million, respectively, while net profit attributable to the owners of the parent company, after deducting non-recurring profit and loss, was RMB147 million, RMB191 million and RMB230 million, respectively, in line with the listing criteriaIn addition, according to the prospectus, Kofiping's research and development investment in 2017-2019 was RMB27 million, RMB0.47 billion and RMB85 million, respectively, amounting to RMB159 million, accounting for 6.07% of total operating income in the last three years. The number of shares to be issued in the IPO of CofiPing is 12.126 million shares, with a proposed financing amount of 1.59 billion yuan, of which 1.39 billion yuan will be used for research and development projects in the pre- and clinical phase of new targeted drugs, and 200 million yuan will be used to supplement working capitalJiang biological: the new crown nucleic acid detection star enterprise, raised 1.356 billion yuan Jiang Bio was established in 2005, is a professional gene diagnostic reagents development, production and sales of innovative enterprises, currently has 20 series of listed products and more than 300 types of PCR kitsOn January 26, 2020, Jiangjiang Bio obtained the first new coronavirus nucleic acid testing kit medical device registration certificate issued by the State Drug AdministrationOn May 22, Jiangjiang Bio-New Crown Virus Nucleic Acid Testing Reagents were included in the WHO Emergency Use List (EUL), which can provide procurement basis for WHO member countries and interested purchasers. According to the prospectus, Jiang's operating income from 2017 to 2019 amounted to 193 million yuan, 224 million yuan and 259 million yuan, respectively, while net profit from non-attributable parent stake was 44.7126 million yuan, 50.4927 million yuan, and 44.3247 million yuan, respectively, in line with the listing criteriaThe company's main business is divided into nucleic acid testing reagents and molecular diagnostic instruments two categories, of which nucleic acid testing kits as the main source of profit, the reporting period sales revenue reached 180 million yuan, 208 million yuan, 221 million yuan, accounting for the same period of operating income of 94.43 percent, 94.03 percent and 97.01 percentIn addition, Jiangjiang Bio's research and development investment in the past three years was RMB 20 00 million, RMB 0.20 billion and RMB 20.23 billion, respectively, amounting to RMB063 million, accounting for 9.32% of total revenue in the last three yearsAccording to the quarterly report of Jiangjiang Bio disclosed, driven by the new crown epidemic, Jiangjiang Bio achieved sales revenue of 224 million yuan in the first quarter of 2020, net profit after deducting non-recurring profit and loss of 0.99 billion yuan, achieving a relatively large increaseThe IPO of The River Bio intends to issue no more than 48.6761 million shares, raising 1.356 billion yuan, mainly for in vitro diagnostic reagent production line upgrade project, molecular diagnostic engineering research and development center construction project, marketing and service network upgrade project, industrial research and development projects and supplementary liquidity. Jinbo Biology: Has found a new target for broad-spectrum suppression of coronavirus, raised 1.196 billion yuan Jinbo Bio was established in 2008, is a joint Fudan University around structural biology, the application of protein engineering and fermentation engineering technology to carry out biological materials, medical end products and functional skin care products production and sales of innovative enterprisesAccording to the prospectus, the company's 2018 and 2019 operating income was RMB128 million and RMB156 million, respectively, while net profit attributable to the parent company after deducting non-recurring gains and losses was RMB41.1342 million and RMB38.299million, respectively, meeting the listing criteria. The main products currently on the market are the beta-milk globulin-related products of acid-thronic cattle and recombinant human-derived type III collagen-related productsAmong them, acid-thronic cattle beta-milk globulin-related products, mainly refers to the effective blocking of HPV infection anti-HPV bioprotein dressing, in 2017-2019 to achieve sales revenue of 0.43 billion yuan, 0.54 billion yuan and 0.60 billion yuan, accounting for the same period of operating income of 44.47 percent, 41.29 percent and 42.33 percentRecombined human origin type III collagen-related products, including various types of medical recombinant human-derived collagen functional dressings and functional skin care products, in the last three years to achieve sales revenue of 0.18 billion yuan, 0.28 billion yuan and 0.60 billion yuan, accounting for the same period of operating income of 18.75 percent, 21.65 percent and 42.54 percentIn addition, according to the prospectus disclosure, Jinbo Bio's cumulative research and development investment in the past three years reached 0.27 billion yuan, accounting for 7.03% of the total cumulative revenue in the last three years. In April 2019, The Research Institute of Jinbo Bio-Fudan University published an article in the journal Science Advances, which found that the polypeptide fusion inhibitor EK1, which can be widely spectruminhibitord with multiple human coronavirus infections, and revealed its action target and functional molecular mechanism, while demonstrating that the HR1 region of the coronatic protrusion protein is an important and conservative drug action target After the outbreak of the new crown, the Team of Fudan University conducted an experimental evaluation of the new coronavirus and found that EK1 polypeptides also had good inhibition effect According to the prospectus disclosure, Jinbo Bio's IPO is intended to issue no more than 20,779,000 shares, raising 1,196 million yuan, mainly for collagen industrialization construction projects, medical device products and broad-spectrum anti-coronavirus new drug research and development projects.